Alejandra Garcia-Glaessner

Alejandra Garcia-Glaessner

Auto-generated profile, based on publicly available information

Alejandra Garcia-Glaessner

Laboratorio de Genómica, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMariana Leguia
Mariana Leguia
AGAlejandra Garcia-Glaessner
Alejandra Garcia-Glaessner
BMBreno Muñoz-Saavedra
Breno Muñoz-Saavedra
DJDiana Juarez
Diana Juarez
PBPatricia Barrera
Patricia Barrera
JLJesus Lescano
Jesus Lescano
Highly pathogenic avian influenza (HPAI) A/H5N1 viruses (lineage 2.3.4.4b) are rapidly invading the Americas, threatening wildlife, poultry, and potentially evolving into the next global pandemic. In November 2022 HPAI arrived in Peru, triggering massive pelican and sea lion die-offs. We report genomic characterization of HPAI/H5N1 in five species of marine mammals and seabirds (dolphins, sea lions, sanderlings, pelicans and cormorants). Peruvian viruses belong to lineage 2.3.4.4b, but they are 4:4 reassortants where 4 genomic segments (PA, HA, NA and MP) position within the Eurasian lineage that initially entered North America from Eurasia, while the other 4 genomic segments (PB2, PB1, NP and NS) position within the American lineage (clade C) that circulated in North America. These viruses are rapidly accruing mutations, including mutations of concern, that warrant further examination and highlight an urgent need for active local surveillance to manage outbreaks and limit spillover into other species, including humans.

30 August 2015 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
DSDeeDee Smart
DeeDee Smart
AGAlejandra Garcia-Glaessner
Alejandra Garcia-Glaessner
DPDiane Palmieri
Diane Palmieri
SWSarah J. Wong-Goodrich
Sarah J. Wong-Goodrich
TKTamalee Kramp
Tamalee Kramp
PSPatricia S. Steeg
Patricia S. Steeg

20 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RZRafal Zielinski
Rafal Zielinski
MHMoinuddin Hassan
Moinuddin Hassan
ILIlya Lyakhov
Ilya Lyakhov
DNDanielle Needle
Danielle Needle
VCVictor Chernomordik
Victor Chernomordik
AGAmir Gandjbakhche
Amir Gandjbakhche
Amplification of the HER2/neu gene and/or overexpression of the corresponding protein have been identified in approximately 20% of invasive breast carcinomas. Assessment of HER2 expression in vivo would advance development of new HER2-targeted therapeutic agents and, potentially, facilitate choice of the proper treatment strategy offered to the individual patient. We present novel HER2-specific probes for in vivo evaluation of the receptor status by near-infrared (NIR) optical imaging. Affibody molecules were expressed, purified, and labeled with NIR-fluorescent dyes. The binding affinity and specificity of the obtained probe were tested in vitro. For in vivo validation, the relationship of the measured NIR signal and HER2 expression was characterized in four breast cancer xenograft models, expressing different levels of HER2. Accumulation of Affibody molecules in tumor tissue was further confirmed by ex vivo analysis. Affibody-DyLight conjugates showed high affinity to HER2 (KD = 3.66±0.26). No acute toxicity resulted from injection of the probes (up to 0.5 mg/kg) into mice. Pharmacokinetic studies revealed a relatively short (37.53±2.8 min) half-life of the tracer in blood. Fluorescence accumulation in HER2-positive BT-474 xenografts was evident as soon as a few minutes post injection and reached its maximum at 90 minutes. On the other hand, no signal retention was observed in HER2-negative MDA-MB-468 xenografts. Immunostaining of extracted tumor tissue confirmed penetration of the tracer into tumor tissue. The results of our studies suggest that Affibody-DyLight-750 conjugate is a powerful tool to monitor HER2 status in a preclinical setting. Following clinical validation, it might provide complementary means for assessment of HER2 expression in breast cancer patients (assuming availability of proper NIR scanners) and/or be used to facilitate detection of HER2-positive metastatic lesions during NIR-assisted surgery.